Portfolio Category: Exits

October 17, 2017

Seahorse Bioscience

Acquired by Agilent Technologies. Developer of tools for measuring cell metabolism.

October 17, 2017

Acquired by Welsh, Carson, Anderson & Stowe. Developer of solutions for the treatment of complex spinal pathologies.

October 17, 2017

Acquired by C.R. Bard. Developer of endovascular devices for the treatment of coronary and peripheral CTO.

October 17, 2017

Acquired by Amgen. Focused on the development of a small molecule therapy for dyslipidemia.

October 17, 2017

Acquired by Johnson & Johnson. Focused on the development of drug-eluting stents to treat coronary artery disease.

October 17, 2017

Acquired by Cephalon. Focused on the development of a biologic therapy for the treatment of asthma.

October 17, 2017

Acquired by Amgen. Focused on the development of an oncolytic vaccine for melanoma and head and neck cancer.

October 17, 2017

Acquired by Allergan. Focused on the development of a small molecule therapy for the treatment of NASH.

October 17, 2017

Acquired by Zoll Medical. Developer of SuperSaturated Oxygen (SSO2) therapy to complement percutaneous coronary intervention.

October 17, 2017

Acquired by Audience. Developer of algorithms and software enabling consumer applications to better understand user contexts and intent.

October 17, 2017

Acquired by Cisco. Developer of advanced optical interconnect technology for high-speed networking applications.

October 17, 2017

Acquired by CyberArk. Provider of encryption-in-use technology which enables businesses to encrypt their data before it goes to the cloud.